MedTrace Logo

Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection

NCT00707850 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2010-08-31

No results posted yet for this study

Summary

Antiviral treatment of HCV in thalassemia has raised concerns of ribavirin-induced hemolysis and increased iron loading. Blood Transfusion in Thalassemic patients are a known high risk for acquiring hepatitis C. The investigators are trying the PEGASYS (Peginterferon alpha-2a(40 KD)) plus Ribavirin in Thalassemic patients with HCV.

Conditions

Interventions

DRUG

PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)

PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: \[=\<75 kg: 1000 mg; \>75 kg: 1200 mg per day (PO)\]

Sponsors & Collaborators

  • Baqiyatallah Research Center for Gastroenterology and Liver Diseases

    collaborator OTHER

  • Tehran Hepatitis Center

    collaborator OTHER

  • Guilan University of Medical Sciences

    collaborator OTHER

  • Tabriz Research Center for Gastroenterology and Liver Diseases

    collaborator UNKNOWN

  • Baqiyatallah Medical Sciences University

    lead OTHER

Principal Investigators

  • Seyed-Moayed Alavian, Professor · Baqiyatallah Research Center for Gastroenterology and Liver Disea

  • Seyyed Mohammad Miri, M.D. · Baqiyatallah Research Center for Gastroenterology and Liver Disea

  • Pegah Karimi, M.D. · Baqiyatallah Research Center for Gastroenterology and Liver Diseases

  • Maryam Keshvari, M.D. · Iranian blood Transfusion Research Center

  • Bita Behnava, M.D. · Baqiyatallah Research Center for Gastroenterology and Liver Diseases

  • Mohammad Hossein Somi, M.D. · Research Center for Gastroenterology and Hepatology, Tabriz University of Medical Sciences, Tabriz

  • Fariborz Mansour-Ghanaei, M.D. · Gastroenterology and Liver Diseases, Gastrointestinal and Liver Diseases Research Center (GLDRC), Guilan University of Medical Sciences, Rasht, Iran

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00707850 on ClinicalTrials.gov